Continuous intra-arterial chemotherapy for downstaging locally advanced oral commissure carcinoma

被引:7
作者
Wu, Chih-Fung [1 ]
Chang, Kao-Ping [1 ]
Huang, Chih-Jen [2 ]
Chen, Chun-Ming [3 ]
Chen, Ching-Yi [3 ]
Lin, Chen-Lung Steve [1 ]
机构
[1] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Coll Med, Dept Surg, Kaohsiung 807, Taiwan
[2] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Coll Med, Kaohsiung 807, Taiwan
[3] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Coll Dent Med, Dept Oral & Maxillofacial Surg, Kaohsiung 807, Taiwan
来源
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2014年 / 36卷 / 07期
关键词
squamous cell carcinoma; oral commissure; intra-arterial infusion; chemotherapy; methotrexate; QUALITY-OF-LIFE; ADVANCED HEAD; NECK-CANCER; INDUCTION CHEMOTHERAPY; OROPHARYNGEAL CANCER; PRIMARY SURGERY; LIP CANCER; CISPLATIN; INFUSION; IRRADIATION;
D O I
10.1002/hed.23408
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Background. The purpose of this study was to assess the usefulness, safety, and efficacy of intra-arterial (IA) infusion chemotherapy for patients with locally advanced oral commissure cancer. Methods. Twenty-one patients with stages III and IV squamous cell carcinoma involving the mouth angle were recruited. Methotrexate (MTX; 50 mg/day) was continuously infused into the external carotid artery for a mean period of 8 days, followed by weekly IA bolus of 25 mg MTX for a mean period of 10 weeks. Results. Thirteen patients (62%) achieved a complete response (CR) and 7 patients (33%) had a partial response (PR). At a median follow-up of 69 months, the estimated 1-year, 3-year, and 5-year survival rates of the patients with CR versus PR were 100% versus 57%, 92% versus 43%, and 80% versus 43%, respectively. Conclusion. Our data demonstrate that continuous IA chemotherapy could achieve a competitive acceptable survival rate and improved locoregional control of advanced oral commissure cancer. (C) 2013 Wiley Periodicals, Inc.
引用
收藏
页码:1027 / 1033
页数:7
相关论文
共 35 条
  • [21] ALTERED PHARMACOKINETICS AND CLINICAL CONSEQUENCES OF LOW-DOSE METHOTREXATE PLUS CISPLATIN IN THE TREATMENT OF ADVANCED HEAD AND NECK-CANCER
    MILANO, G
    THYSS, A
    RENEE, N
    VALLICIONI, J
    SANTINI, J
    SCHNEIDER, M
    DEMARD, F
    [J]. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1986, 22 (07): : 843 - 847
  • [22] Molinari R, 1999, INTRAARTERIAL CHEMOT, P148
  • [23] The evolving role of combined modality therapy in head and neck cancer
    Robbins, KT
    [J]. ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2000, 126 (03) : 265 - 269
  • [24] Robbins KT, 1996, ARCH OTOLARYNGOL, V122, P853
  • [25] Health-related quality of life and clinical function after primary surgery for oral cancer
    Rogers, SN
    Lowe, D
    Fisher, SE
    Brown, JS
    Vaughan, ED
    [J]. BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY, 2002, 40 (01) : 11 - 18
  • [26] Rohde S, 2005, AM J NEURORADIOL, V26, P1804
  • [27] Surgical Treatment of Lip Cancer: Our Experience With 106 Cases
    Salgarelli, Attilio Carlo
    Sartorelli, Francesco
    Cangiano, Alessandro
    Pagani, Renato
    Collini, Marco
    [J]. JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2009, 67 (04) : 840 - 845
  • [28] SUPERSELECTIVE INTRAARTERIAL CHEMOTHERAPY IN COMBINATION WITH IRRADIATION - PRELIMINARY-REPORT
    SHIMIZU, T
    SAKAKURA, Y
    HATTORI, T
    YAMAGUCHI, N
    KUBO, M
    SAKAKURA, K
    [J]. AMERICAN JOURNAL OF OTOLARYNGOLOGY, 1990, 11 (02) : 131 - 136
  • [29] Sikes Jr JW, 2004, PETERSONS PRINCIPLES, P659
  • [30] SOBIN LH, 2002, UICC INT UNION CANC, P19